

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CATALENT PHARMA SOLUTIONS, INC.,
Petitioner

v.

PATHEON SOFTGELS INC.,
Patent Owner

Case IPR2018-00422
U.S. Pat. No. 9,693,979

PATHEON SOFTGELS INC.'S EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

IPR2018-00422

Patent 9,693,979 B2

<i>Patheon Exhibit #</i>	<i>Description</i>
2001	Declaration of Mansoor Khan, R.Ph., Ph.D.
2002	<i>Curriculum Vitae</i> for Mansoor Khan, R.Ph., Ph.D.
2003	Serajuddin, A., “Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises, Subsequent Problems, and Recent Breakthroughs,” <i>J. Pharm. Sci.</i> , 88:1058–1066 (1999)
2004	Patravale, V.B. <i>et al.</i> , “Nanosuspensions: a promising drug delivery strategy,” <i>J. Pharm. & Pharmacol.</i> , 56:827–840 (2004)
2005	WO 95/31979 to Shelley <i>et al.</i> , “Solutions of Aryl or Heteroaryl Substituted Alkanoic Acids in Lipophilic Solvents and Soft Gelatin Capsules Containing Such Solutions” (Nov. 30, 1995)
2006	Ranucci <i>et al.</i> , “Pharmacokinetic results on naproxen prodrugs based on poly(ethyleneglycol)s,” <i>J. Biomater. Sci. Polymer Edn.</i> , 6:141–147 (1994)
2007	WO 95/31194 to Shapiro, H., “Compositions for Treatment of Chronic Inflammatory Diseases” (Nov. 23, 1995)
2008	Shah <i>et al.</i> , “ <i>In Vitro</i> Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants,” <i>Pharm Res.</i> 6:612-618 (1989)
2009	Crowley and Martini, “Physicochemical Approaches to Enhancing Oral Absorption,” <i>Pharm. Tech. Eur.</i> , 16:18-27 (2004)
2010	Serajuddin <i>et al.</i> , “Water Migration from Soft Gelatin Capsule Shell to Fill Material and Its Effect on Drug Solubility,” <i>J. Pharm. Sci.</i> , 75:62-64 (1986)
2011	Merisko-Liversidge <i>et al.</i> , “Nanosizing: a formulation approach for poorly-water-soluble compounds,” <i>Eur. J. Pharm. Sci.</i> , 18:113-120 (2003)
2012	Naprosyn [®] , Physician’s Desk Reference, 48 th ed., 2363–2365 (1994)
2013	Anaprox [®] , Physician’s Desk Reference, 48 th ed., 2350–2352 (1994)
2014	Aleve [®] , Physician’s Desk Reference, 49 th ed., 1910 (1995)
2015	Naprelan [®] , Physician’s Desk Reference, 53 rd ed., 3335–3337 (1999)

IPR2018-00422

Patent 9,693,979 B2

<i>Patheon Exhibit #</i>	<i>Description</i>
2016	FDA Approved Products: Naprosyn [®] , available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017581 , last accessed May 19, 2018
2017	FDA Approved Products: Anaprox [®] , available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018164 , last accessed May 19, 2018
2018	FDA Approved Products: Naprelan [®] , available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020353 , last accessed May 19, 2018
2019	FDA Approved Products: Aleve [®] , available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020204 , last accessed May 19, 2018
2020	FDA Approved Products: Naproxen Sodium Soft Gelatin Capsules, available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021920 , last accessed May 19, 2018
2021	Tabibi and Gupta, “Soft Gelatin Capsules Development,” in <i>Water Insoluble Drug Formulation</i> , Chapter 17, pp. 609–633, Interpharm Press (2000)
2022	Seager and Slabaugh, “Acids, Bases, and Salts,” in <i>Introductory Chemistry</i> , Chapter 9, Scott, Forsman and Co. (1979)
2023	Gennadios, “Soft Gelatin Capsules,” in <i>Protein-Based Films and Coatings</i> , Chapter 16, pp. 393 – 443, CRC Press LTD (2002)
2024	Recorded Assignments for U.S. Patent Nos. 9,693,978 and 9,693,979, Reel 043042, Frame 0619 to 0652 (recorded June 29, 2017)
2025	International Conference on Harmonisation, “Topic Q3B: ICH Harmonised Tripartite Guideline for Impurities in New Medicinal Products,” (November 6, 1996)
2026	The Merck Index, Merck & Co., Inc., 12 th Ed. (1996), pp. xii-xvii, 392-393, 641-642, 763-764, 911, 1101, 1305, 1320, and 1349

IPR2018-00422
Patent 9,693,979 B2

<i>Patheon Exhibit #</i>	<i>Description</i>
2027	Chang, R., "Chemistry," 6 th ed., Ch. 15, pp. 597–641, McGraw-Hill (1998)

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

/Eldora L. Ellison/

Eldora L. Ellison, Ph.D.

Lead Counsel for Patent Owner

Registration No. 39,967

Date: May 22, 2018

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

9372675_1.DOC

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))

The undersigned hereby certifies that the above-captioned Patheon Softgels Inc.'s Exhibit List, along with Exhibits 2001-2027, were served in their entirety on May 22, 2018, upon the following parties via email:

Gregory L. Porter:	GregPorter@andrewskurth.com
Rose Cordero Prey:	rprey@andrewskurthkenyon.com
David Bradin:	DavidBradin@andrewskurth.com

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

/Eldora L. Ellison/

Eldora L. Ellison, Ph.D.

Lead Counsel for Patent Owner

Registration No. 39,967

Date: May 22, 2018

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600